Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | HEXA | P06865 | 1/20 | 0.31 |
| ▸ | HEXB | P07686 | 1/20 | 0.31 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440165 | 0.89 | MTNR1A (0.31) | — | |
| SCHEMBL6438262 | 0.83 | RYR2 (0.39) | AHRMAPTMEN1KMT2ARYR2 | |
| SCHEMBL6438585 | 0.74 | AHR (0.41) | AHRCYP19A1MAPT | |
| SCHEMBL13939409 | 0.73 | L3MBTL1 (0.35) | MAPTALOX12MEN1KMT2AHEXA | |
| SCHEMBL13939592 | 0.72 | AHR (0.40) | AHRCYP19A1MAPTMEN1KMT2A | |
| SCHEMBL13939397 | 0.72 | HRH3 (0.33) | MAPTMEN1KMT2A | |
| SCHEMBL6439091 | 0.72 | SLC2A1 (0.43) | AHRCYP19A1MAPTMEN1KMT2A | |
| SCHEMBL13940042 | 0.69 | ACHE (0.44) | AHRCYP19A1MAPT | |
| SCHEMBL6437151 | 0.69 | SMN1; SMN2 (0.39) | MEN1KMT2A | |
| SCHEMBL2842324 | 0.66 | ALDH1A1 (0.41) | AHRMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | AHR 3933/4885CYP19A1 2682/4885MAPT 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.